Allergan Plc (NYSE:AGN)

CAPS Rating: 4 out of 5

The Company is engaged in the development, manufacture, marketing, sale and distribution of brand and off-patent pharmaceutical products.

Results 1 - 20 of 42 : 1 2 3 Next »

Recs

0
Member Avatar Ajormond (< 20) Submitted: 4/16/2016 10:08:43 AM : Outperform Start Price: $215.30 AGN Score: +0.98

Allergan has taken a recent hit with the recent walk away from merger talks. It is clear that Wall Street is not certain that the deal with Teva will be completed either. I believe that the divestiture will be completed and that Allergan will reduce the debt on it's books. In addition, Allergan has many late stage drugs and devices in the pipeline that will increase top line growth.

Recs

0
Member Avatar pdelaun (76.65) Submitted: 4/15/2016 5:36:36 PM : Outperform Start Price: $215.30 AGN Score: +0.98

I'll be riding this to $275 a share (on CAPS and in realsies)

Recs

0
Member Avatar optioncoach (90.24) Submitted: 4/5/2016 3:50:05 PM : Outperform Start Price: $234.98 AGN Score: -8.96

This got killed for a rule that the US Treasury put on. I like them at this level. Probably carries a bunch of risk, but 15% in a day is a lot. Let's see where it takes us.

Recs

0
Member Avatar SgtTurbo (52.02) Submitted: 3/18/2016 12:19:58 PM : Outperform Start Price: $272.14 AGN Score: -21.25

Trading at a discount to the likely merger with Pfizer, along with strong drug sale growth.

Recs

0
Member Avatar graybell (< 20) Submitted: 1/21/2016 3:46:14 PM : Outperform Start Price: $296.00 AGN Score: -37.02

arb

Recs

0
Member Avatar Merlinsmoney (89.13) Submitted: 1/3/2016 6:14:23 PM : Outperform Start Price: $306.50 AGN Score: -32.26

Good future in healthcare area.

Recs

0
Member Avatar roymarshall (28.88) Submitted: 11/23/2015 3:44:54 PM : Underperform Start Price: $302.36 AGN Score: +27.09

Challenges for the company are just beginning. Beware.

Recs

0
Member Avatar reimerpdx (61.11) Submitted: 11/12/2015 10:48:59 AM : Outperform Start Price: $311.02 AGN Score: -30.13

Due to the Pfizer merger, or barring that, their cashflow after sale to TEVA.

Recs

0
Member Avatar marsuculix (< 20) Submitted: 9/16/2015 1:52:47 AM : Outperform Start Price: $302.59 AGN Score: -32.21

a solid performer !

Recs

0
Member Avatar wa7wmx1 (< 20) Submitted: 8/28/2015 5:51:13 PM : Outperform Start Price: $310.85 AGN Score: -34.48

Given its track record from once Watkins Pharma, I suspect that AGN's management will accept nothing less than excellence from the company. However I doubt that AGN's management would take the time to let me interview them. Hence I subscribe to TMF.

Recs

0
Member Avatar murphydevani (70.41) Submitted: 8/26/2015 1:17:02 AM : Underperform Start Price: $299.77 AGN Score: +35.18

Target $288 - $285 - $281 - $279 - $270

Recs

0
Member Avatar tradersam3 (39.06) Submitted: 8/6/2015 6:46:36 PM : Outperform Start Price: $320.20 AGN Score: -31.49

Great Management. Has a clear view of future.

Recs

0
Member Avatar CellBlock9 (91.26) Submitted: 4/26/2015 11:03:34 AM : Outperform Start Price: $296.95 AGN Score: -24.25

mgk, 295.41

Recs

0
Member Avatar derbydog85 (< 20) Submitted: 3/17/2015 8:19:30 PM : Outperform Start Price: $308.50 AGN Score: -29.29

Botox use might be used for depression....Growth pharma company has great pipeline...Plenty of upside ahead.

Recs

0
Member Avatar zojo360 (< 20) Submitted: 3/7/2015 2:58:20 PM : Outperform Start Price: $295.29 AGN Score: -25.19

A key element to Actavis’ growth has been the so-called patent cliff, a period when many of the world’s best-selling drugs are losing patent protection. In fact, Actavis has specifically mentioned in the past the new generic introduction of drugs such as Suboxone, Lidoderm and Concerta as growth drivers.

The UBS price target for the stock is $333. The Thomson/First Call consensus price target is lower at $313.11. Shares closed Tuesday at $296.23.

Recs

0
Member Avatar benyboy (< 20) Submitted: 3/5/2015 9:23:55 AM : Outperform Start Price: $297.10 AGN Score: -25.07

John Paulson

Recs

0
Member Avatar pythonmonte (69.92) Submitted: 2/21/2015 8:46:54 PM : Outperform Start Price: $296.43 AGN Score: -24.76

I hears its one of the four horse men of the apolcospe yhe other 3 GILD,REGN,Clgn.

Recs

0
Member Avatar tripleking (50.51) Submitted: 6/17/2014 10:21:35 AM : Outperform Start Price: $213.00 AGN Score: -4.35

good stock

Recs

0
Member Avatar DugdaleTiki (46.67) Submitted: 3/3/2014 9:27:18 AM : Outperform Start Price: $213.00 AGN Score: -10.05

2014 Sabrient Pick

Recs

0
Member Avatar StewpotDrew (< 20) Submitted: 2/3/2014 12:13:39 AM : Outperform Start Price: $190.00 AGN Score: -1.97

Drugs.

Results 1 - 20 of 42 : 1 2 3 Next »

Featured Broker Partners